Search
Exelixis Inc
EXELAdd to Watchlist
55.790USD
+0.420+0.76%
Close 07-24 16:00（ET）Quotes delayed by 15 min
14.64BMarket Cap
17.86P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-24The current earnings forecast score of Exelixis Inc is 7.05, ranking 310 out of 386 in the Biotechnology & Medical Research industry. The average price target is 45.50, with a high of 60.00 and a low of 30.00.
Analyst Rating
Based on
20
analysts
Hold
Current Rating
52.189
Target Price
-5.75%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Exelixis Inc
EXEL
20
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Exelixis Inc's expected revenue for the next quarter?
Exelixis Inc's expected revenue is 635.95M.
What is Exelixis Inc's price target?
Analysts forecast that Exelixis Inc's price target is USD 45.50, with the highest forecast at USD 60.00 and the lowest forecast at USD 30.00.
How have Exelixis IncEXEL's recent earnings per share performed?
The market expectation was USD 0.81, while Exelixis IncEXEL's earnings per share (EPS) for the previous quarter was USD 0.92. EPS for the next quarter is expected at USD 0.79.
What is the analyst rating for Exelixis Inc?
Based on the ratings of Exelixis Inc's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.